About: Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncol

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncol Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 27 October 2008

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2008 (ast) наукова стаття, опублікована в жовтні 2008 (uk) مقالة علمية نشرت في 27 أكتوبر 2008 (ar) scientific article published on 27 October 2008 (en)
publication date	wds:Q37117099-2F06C3D9-8459-44A8-B193-844E865D33C6
publication date	2008-10-27 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37117099-A6C72A75-5BF5-4232-B092-0637DE76B97A
language of work or name	English
cites work	wds:Q37117099-05EF27CB-D84C-4FD7-84B4-2EF2A7999413 wds:Q37117099-0F0878EB-D01A-4144-B073-3EC184F16C82 wds:Q37117099-15555AE7-6E42-489D-B34F-8F767A10855A wds:Q37117099-2F8B39CE-285B-4B10-B351-A14F73E56024 wds:Q37117099-31131A54-6DC4-4F78-AB8F-5ACEBAC4E043 wds:Q37117099-391C0C95-E417-42F6-A3BA-9BCA052D6365 wds:Q37117099-4106D481-AF92-41D8-8A93-1D261F4842CE wds:Q37117099-46762080-3C8E-45AE-869B-FD11E2F38B79 wds:Q37117099-51C6822E-075A-4984-ADA6-CFCB2FEC7A61 wds:Q37117099-533875D0-B0E4-48C8-AAD3-FFB7DCE73A97 wds:Q37117099-55334534-32F1-4A03-B736-9E7F0D983A31 wds:Q37117099-5766FE2C-353C-43FE-A143-F229CD3B3A32 wds:Q37117099-6B659862-DA75-41DE-883E-A748450F000D wds:Q37117099-89166877-99CA-42DC-872F-11000E7EEFD7 wds:Q37117099-892B5DB7-2934-4694-91A0-7BB3C4B28C62 wds:Q37117099-9CEF590D-5FFF-4BCA-B27F-CC37A35F4D78 wds:Q37117099-9F795FB2-BE13-4A60-B7D8-04D1948B74F9 wds:Q37117099-AA9712BE-CD08-4A6A-AA0B-E8FE362DDC08 wds:Q37117099-AAD87005-90D4-4F06-93EB-F84325CABA40 wds:Q37117099-AFC73064-782B-4B76-BFAF-B0D701FA2250 wds:Q37117099-B64A939B-53E7-4696-B38C-F968C14EF5E3 wds:Q37117099-BD3E6D63-EB14-4DF7-B279-5909DDAD0BE8 wds:Q37117099-BF742C1D-8CF5-4661-AC32-0D3493041418 wds:Q37117099-C0630700-1BD4-4164-B406-3C893A02D236 wds:Q37117099-D8A11A9C-4422-4FDF-B9B6-429455F6C042 wds:Q37117099-DAF266E2-8772-470E-93C8-CAB9B0DA54D2 wds:Q37117099-F434F662-A225-451C-8298-086334E4636A wds:Q37117099-F73944B7-1A81-43EA-92A1-0B185236BE78
cites work	Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis PDGFRA activating mutations in gastrointestinal stromal tumors. Biology of gastrointestinal stromal tumors. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trial Mutations in c-kit gene exons 9 and 13 in gastrointestinal stromal tumors among Japanese. KIT-negative gastrointestinal stromal tumors with a long term follow-up: a new subgroup does exist KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT.
author name string	wds:Q37117099-19D6EED8-9B4E-448C-8F78-A08AD181202C wds:Q37117099-256D8153-8B04-4DA9-9CE8-2F4A53329859 wds:Q37117099-3C4F6873-3716-406B-AAFA-6AE97F69934B wds:Q37117099-623D4635-8AB0-4842-8E22-E5641E3791C8 wds:Q37117099-75596191-7C56-4FD2-BA64-7D665811700E wds:Q37117099-7616C855-5AAC-4EDC-8749-7FEEE536D919 wds:Q37117099-90F65F98-6EA1-4FC8-B298-0516CDDA53DA wds:Q37117099-9B24B97B-6ADB-4439-9EB9-D39FE331779B wds:Q37117099-AAC24E63-B9DE-4BFC-8AD5-B36DBC6EF364 wds:Q37117099-E9CA38EC-374C-4997-99B0-5EB913283240 wds:Q37117099-EAB10475-712D-4B3D-BB04-8E536F62B1E4
author name string	Jonathan A Fletcher Kouros Owzar Christopher D M Fletcher Charles D Blanke Robert S Benjamin Christopher W Ryan Ernest C Borden Christopher L Corless Cathryn Rankin Donna Hollis Vivien H Bramwell
rdfs:label	Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncol (en)

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software